Eli Lilly and Company $LLY Shares Sold by Bank & Trust Co

Key Points

• Bank & Trust Co. reduced its Eli Lilly stake by 8.6% in the third quarter, selling 947 shares and retaining 10,054 shares valued at approximately $11.6 million. Institutional investors and hedge funds collectively own 82.53% of LLY.
• Eli Lilly reported strong quarterly results, with revenue up 47.7% year over year to $22.97 billion and EPS of $8.38, exceeding estimates. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $1,312.36.
• The company’s growth outlook is supported by Mounjaro, Zepbound, and its developing oral GLP-1 drug Foundayo, but high valuation, potential price pressure, and uncertainty over broader obesity-treatment adoption remain key risks.

Bank & Trust Co decreased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,054 shares of the company's stock after selling 947 shares during the quarter. Eli Lilly and Company comprises 5.8% of Bank & Trust Co's holdings, making the stock its 3rd largest position. Bank & Trust Co's holdings in Eli Lilly and Company were worth $11,633,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter worth $13,522,666,000. Jupiter Topco LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at about $4,667,180,000. Fifth Third Bancorp increased its holdings in shares of Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock worth $1,805,959,000 after buying an additional 1,497,423 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Eli Lilly and Company by 353.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company's stock worth $1,425,859,000 after buying an additional 1,208,510 shares during the last quarter. Finally, Corient Private Wealth LP purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $764,116,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last ninety days. 0.14% of the stock is owned by corporate insiders.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong GLP-1 growth outlook: Analysts remain constructive on Lilly’s Mounjaro and Zepbound franchises, while anticipated momentum from the oral GLP-1 candidate Foundayo could support growth in the second half of 2026. Recent data presented at a diabetes meeting showed Foundayo produced greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes, although commercial and regulatory execution remain important. Eli Lilly's Breakout May Occur Soon - H2'26 Foundayo Tailwinds
• Positive Sentiment: Pipeline diversification: Lilly is working to reduce reliance on obesity and diabetes products through oncology, immunology, neuroscience, and other areas. The FDA granted orphan-drug designation to experimental cancer treatment olomorasib, providing potential development incentives and exclusivity benefits. Lilly also expanded its drug-discovery collaboration with Gate Bioscience in a deal potentially worth more than $870 million. Eli Lilly Stock Gains on Regulatory Win
• Positive Sentiment: Additional development progress: Early-stage updates for elt­re­kibart and a new basal-insulin candidate point to continued investment in Lilly’s pipeline. Its partnership with insitro is also making machine-learning tools available through Lilly TuneLab, potentially improving external drug discovery and future licensing opportunities. Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone
• Neutral Sentiment: Upcoming earnings focus: Investor attention is building ahead of third-quarter results. Recent coverage points to improving operating momentum, but expectations are already high following the company’s prior revenue and earnings outperformance.
• Negative Sentiment: Valuation and concentration risks: Commentary warns that Lilly trades at a substantial premium to the broader market, leaving limited room for disappointing sales, pricing, or guidance. Falling U.S. prices for Zepbound and Mounjaro could also pressure future margins or growth assumptions. Eli Lilly: Impressive Growth, Questionable Valuation
• Negative Sentiment: Childhood-obesity guidance: New World Health Organization guidelines discourage certain approaches to treating childhood and adolescent obesity, creating potential uncertainty around how quickly GLP-1 therapies could expand in younger populations. WHO Childhood Obesity Guidelines

Eli Lilly and Company Trading Up 3.4%

NYSE LLY traded up $39.89 during trading on Wednesday, hitting $1,197.38. The stock had a trading volume of 1,165,722 shares, compared to its average volume of 2,967,986. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $1.13 trillion, a PE ratio of 40.19, a PEG ratio of 1.40 and a beta of 0.46. The firm has a 50 day moving average price of $1,173.98 and a 200 day moving average price of $1,092.69. Eli Lilly and Company has a twelve month low of $783.85 and a twelve month high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. During the same quarter in the prior year, the company earned $6.31 earnings per share. The business's quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on LLY shares. Leerink Partners increased their price objective on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a research report on Thursday, June 25th. The Goldman Sachs Group upped their price target on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the company a "buy" rating in a research note on Thursday, September 17th. BMO Capital Markets reiterated an "outperform" rating on shares of Eli Lilly and Company in a report on Thursday, October 1st. Bank of America raised their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. Finally, Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Sunday, August 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $1,312.36.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.